{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:15:19Z","timestamp":1762175719980},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The purpose of this report is to summarize information on drugs recently approved by the U.S. Food and Drug Administration. Three drugs have recently been approved: Gleevec\u2122 (imatinib mesylate) at a starting dose of 400 or 600 mg daily for the treatment of malignant unresectable and\/or metastatic gastrointestinal stromal tumors; Mesnex\u00ae (mesna) tablets as a prophylactic agent to reduce the incidence of ifosfamide-induced hemorrhagic cystitis, and Zometa\u00ae (zoledronic acid) for the treatment of patients with multiple myeloma and for patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. The recommended dose and schedule is 4 mg infused over 15 minutes every 3-4 weeks. These three drugs represent three different types of drug approval: Gleevec is an accelerated approval and supplemental new drug application (NDA); Mesnex tablets represent an oral formulation of a drug approved 14 years ago as an intravenous formulation, and Zometa represents a standard NDA for a noncytotoxic, supportive-care drug. Information provided includes rationale for drug development, study design, efficacy and safety results, and pertinent literature references.<\/jats:p>","DOI":"10.1634\/theoncologist.7-5-393","type":"journal-article","created":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T21:38:39Z","timestamp":1093383519000},"page":"393-400","source":"Crossref","is-referenced-by-count":42,"title":["U.S. Food and Drug Administration Drug Approval Summaries: Imatinib Mesylate, Mesna Tablets, and Zoledronic Acid"],"prefix":"10.1093","volume":"7","author":[{"given":"Martin H.","family":"Cohen","sequence":"first","affiliation":[{"name":"Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramzi","family":"Dagher","sequence":"additional","affiliation":[{"name":"Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna J.","family":"Griebel","sequence":"additional","affiliation":[{"name":"Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amna","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Martin","sequence":"additional","affiliation":[{"name":"Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy S.","family":"Scher","sequence":"additional","affiliation":[{"name":"Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald H.","family":"Sokol","sequence":"additional","affiliation":[{"name":"Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant A.","family":"Williams","sequence":"additional","affiliation":[{"name":"Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Pazdur","sequence":"additional","affiliation":[{"name":"Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2002,10,1]]},"reference":[{"key":"2021122216323957400_R1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10434-000-0705-6","article-title":"Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management","volume":"7","author":"Pidhorecky","year":"2000","journal-title":"Ann Surg Oncol"},{"key":"2021122216323957400_R2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"key":"2021122216323957400_R3","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1357-2725(99)00076-X","article-title":"The biology of stem cell factor and its receptor c-kit","volume":"31","author":"Ashman","year":"1999","journal-title":"Int J Biochem Cell Biology"},{"key":"2021122216323957400_R4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0002-9440(10)65250-9","article-title":"Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas","volume":"154","author":"Lasota","year":"1999","journal-title":"Am J Pathol"},{"key":"2021122216323957400_R5","first-page":"4297","article-title":"Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors","volume":"59","author":"Taniguchi","year":"1999","journal-title":"Cancer Res"},{"key":"2021122216323957400_R6","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0002-9440(10)64946-2","article-title":"KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors","volume":"156","author":"Lux","year":"2000","journal-title":"Am J Pathol"},{"key":"2021122216323957400_R7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0002-9440(10)64343-X","article-title":"The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors","volume":"160","author":"Andersson","year":"2002","journal-title":"Am J Pathol"},{"key":"2021122216323957400_R8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11864-000-0039-4","article-title":"Gastrointestinal stromal tumors","volume":"1","author":"Casper","year":"2000","journal-title":"Curr Treat Options Oncol"},{"key":"2021122216323957400_R9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00000658-200001000-00008","article-title":"Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival","volume":"231","author":"DeMatteo","year":"2000","journal-title":"Ann Surg"},{"key":"2021122216323957400_R10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/BF02303698","article-title":"Primary gastrointestinal sarcomas: analysis of prognostic variables","volume":"2","author":"Conlon","year":"1995","journal-title":"Ann Surg Oncol"},{"key":"2021122216323957400_R11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia","volume":"105","author":"Druker","year":"2000","journal-title":"J Clin Invest"},{"key":"2021122216323957400_R12","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"2021122216323957400_R13","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2021122216323957400_R14","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM200104053441404","article-title":"Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor","volume":"344","author":"Joensuu","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122216323957400_R15","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1200\/JCO.1999.17.10.3333","article-title":"American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants","volume":"17","author":"Hensley","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122216323957400_R16","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/0277-5379(82)90143-2","article-title":"Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention\u2014III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna)","volume":"18","author":"Brock","year":"1982","journal-title":"Eur J Cancer Clin Oncol"},{"key":"2021122216323957400_R17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/BF01612769","article-title":"Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders","volume":"117","author":"Fukuoka","year":"1991","journal-title":"J Cancer Res Clin Oncol"},{"key":"2021122216323957400_R18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0305-7372(87)90030-2","article-title":"Mesna and oxazaphosphorine cancer chemotherapy","volume":"14","author":"Shaw","year":"1987","journal-title":"Cancer Treat Rev"},{"key":"2021122216323957400_R19","first-page":"1460","article-title":"Blood thiols following amifostine and mesna infusions, a Pediatric Oncology Group study","volume":"29","author":"Souid","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"2021122216323957400_R20","first-page":"2313","article-title":"Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects","volume":"4","author":"Goren","year":"1998","journal-title":"Clin Cancer Res"},{"key":"2021122216323957400_R21","first-page":"4358","article-title":"Reduction of dimesna to mesna by the isolated perfused rat liver","volume":"58","author":"Goren","year":"1998","journal-title":"Cancer Res"},{"key":"2021122216323957400_R22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/BF02555852","article-title":"Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone","volume":"49","author":"Flanagan","year":"1991","journal-title":"Calcif Tissue Int"},{"key":"2021122216323957400_R23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122216323957400_R24","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122216323957400_R25","first-page":"630","article-title":"Bone metastases: improving the therapeutic index","volume":"21","author":"Scher","year":"1994","journal-title":"Semin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.7-5-393","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.7-5-393","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/7\/5\/393\/41838690\/oncolo_7_5_393.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/7\/5\/393\/41838690\/oncolo_7_5_393.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T19:37:31Z","timestamp":1640201851000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/7\/5\/393\/6397228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10,1]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2002,10,1]]},"published-print":{"date-parts":[[2002,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.7-5-393","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2002,10,1]]},"published":{"date-parts":[[2002,10,1]]}}}